Attached files

file filename
8-K/A - AMENDMENT NO. 1 TO FORM 8-K - ViewRay, Inc.d89741d8ka.htm
EX-99.2 - EX-99.2 - ViewRay, Inc.d89741dex992.htm
EX-99.3 - EX-99.3 - ViewRay, Inc.d89741dex993.htm
Index to Financial Statements

Exhibit 99.1

VIEWRAY TECHNOLOGIES, INC.

INDEX TO FINANCIAL STATEMENTS

 

     Page  

Balance Sheets

     2   

Statements of Operations

     3   

Statements of Convertible Preferred Stock and Stockholders’ Deficit

     4   

Statements of Cash Flows

     5   

Notes to Financial Statements

     6   

 

1


Index to Financial Statements

VIEWRAY TECHNOLOGIES, INC.

Balance Sheets

(In thousands, except share and per share data)

(Unaudited)

 

     June 30,
2015
    December 31,
2014
 

ASSETS

    

Current assets:

    

Cash and cash equivalents

   $ 17,698      $ 11,129   

Accounts receivable

     —          904   

Inventory

     8,288        8,238   

Deposits on purchased inventory

     4,225        2,798   

Deferred cost of revenue

     8,540        4,712   

Prepaid expenses and other current assets

     1,012        626   
  

 

 

   

 

 

 

Total current assets

     39,763        28,407   

Property and equipment, net

     3,498        2,931   

Restricted cash

     553        1,053   

Intangible assets, net

     181        264   

Deferred offering costs

     532        1,419   

Other assets

     31        31   
  

 

 

   

 

 

 

TOTAL ASSETS

   $ 44,558      $ 34,105   
  

 

 

   

 

 

 

LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

    

Current liabilities:

    

Notes payable

   $ 240      $ 240   

Accounts payable

     4,195        6,134   

Accrued liabilities

     4,588        4,436   

Customer deposits

     8,140        6,100   

Deferred revenue, current portion

     9,830        7,361   

Long-term debt, current portion

     —          5,493   
  

 

 

   

 

 

 

Total current liabilities

     26,993        29,764   

Long-term debt, net of current portion

     27,386        9,149   

Convertible preferred stock warrant liability

     87        138   

Other long-term liabilities

     347        567   
  

 

 

   

 

 

 

TOTAL LIABILITIES

     54,813        39,618   
  

 

 

   

 

 

 

Commitments and contingencies (Note 7)

    

Convertible preferred stock, par value $0.01 per share; 80,710,997 and 74,460,997 shares authorized at June 30, 2015 (unaudited) and December 31, 2014; 30,381,987 and 27,654,928 shares issued and outstanding at June 30, 2015 (unaudited) and December 31, 2014; aggregate liquidation preference of $162,682 and $146,732 at June 30, 2015 (unaudited) and December 31, 2014, actual

     160,839        145,110   

Stockholders’ deficit:

    

Common stock, par value of $0.01 per share; 90,000,000 and 88,000,000 shares authorized at June 30, 2015 (unaudited) and December 31, 2014; 920,851 and 907,037 shares issued and outstanding at June 30, 2015 (unaudited) and December 31, 2014

     9        9   

Additional paid-in capital

     1,572        1,414   

Accumulated deficit

     (172,675     (152,046
  

 

 

   

 

 

 

TOTAL STOCKHOLDERS’ DEFICIT

     (171,094     (150,623
  

 

 

   

 

 

 

TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT

   $ 44,558      $ 34,105   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these financial statements.

 

2


Index to Financial Statements

VIEWRAY TECHNOLOGIES, INC.

Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

 

     Six Months Ended June 30,  
     2015     2014  

Revenue:

    

Product

   $ 99      $ 3,267   

Service

     363        70   
  

 

 

   

 

 

 

Total revenue

     462        3,337   

Cost of revenue:

    

Product

     545        5,105   

Service

     1,065        255   
  

 

 

   

 

 

 

Total cost of revenue

     1,610        5,360   
  

 

 

   

 

 

 

Gross margin

     (1,148     (2,023

Operating expenses:

    

Research and development

     4,506        5,160   

Selling and marketing

     2,191        2,579   

General and administrative

     11,497        5,912   
  

 

 

   

 

 

 

Total operating expenses

     18,194        13,651   
  

 

 

   

 

 

 

Loss from operations

     (19,342     (15,674

Interest income

     1        —     

Interest expense

     (1,323     (980

Other income (expense), net

     35        43   
  

 

 

   

 

 

 

Loss before provision for income taxes

   $ (20,629   $ (16,611

Provision for income taxes

     —          —    
  

 

 

   

 

 

 

Net loss

   $ (20,629   $ (16,611
  

 

 

   

 

 

 

Deemed capital contribution on repurchase of Series A preferred stock

   $ —        $ 9   
  

 

 

   

 

 

 

Net loss attributable to common stockholders

   $ (20,629   $ (16,602
  

 

 

   

 

 

 

Net loss per share attributable to common stockholders, basic and diluted

   $ (22.52   $ (18.85
  

 

 

   

 

 

 

Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted

     916,017        880,708   
  

 

 

   

 

 

 

The accompanying notes are an integral part of these financial statements.

 

3


Index to Financial Statements

VIEWRAY TECHNOLOGIES, INC.

Statements of Convertible Preferred Stock and Stockholders’ Deficit

(In thousands, except share data)

(Unaudited)

 

    

 

Convertible Preferred Stock

    

 

Common Stock

     Additional
Paid-in
Capital
     Accumulated
Deficit
    Total
Stockholders’
Deficit
 
     Shares      Amount      Shares      Amount          

Balance at December 31, 2014

     27,654,928       $ 145,110         907,037       $ 9       $ 1,414       $ (152,046   $ (150,623

Issuance of common stock from option exercises (unaudited)

     —          —          13,814         —          10         —         10   

Stock-based compensation (unaudited)

     —          —          —          —          148         —         148   

Issuance of Series C Preferred, net of issuance cost of $221,100 (unaudited)

     2,727,059         15,729         —          —          —          —         —    

Net loss (unaudited)

     —          —          —          —          —          (20,629     (20,629
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

Balance at June 30, 2015 (unaudited)

     30,381,987       $ 160,839         920,851       $ 9       $ 1,572       $ (172,675   $ (171,094
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

 

The accompanying notes are an integral part of these financial statements.

 

4


Index to Financial Statements

VIEWRAY TECHNOLOGIES, INC.

Statements of Cash Flows

(In thousands)

(Unaudited)

 

     Six Months Ended June 30,  
     2015     2014  

CASH FLOWS FROM OPERATING ACTIVITIES:

    

Net loss

   $ (20,629   $ (16,611

Adjustments to reconcile net loss to net cash used in operating activities:

    

Depreciation and amortization

     591        489   

Stock-based compensation

     148        204   

Change in fair value of convertible preferred stock warrant liability

     (51     (55 )

Inventory lower of cost and market adjustment

     308        598   

Write-off of deferred offering cost

     2,920        —     

Amortization of debt discount and interest accrual

     123        94   

Changes in operating assets and liabilities:

    

Accounts receivable

     904        (3,210

Inventory

     (358     (3,058

Deposits on purchased inventory

     (1,427     (488

Deferred costs

     (3,828     —     

Prepaid expenses and other current assets

     (386     (76

Accounts payable

     (3,008     2,339   

Accrued expenses and other long-term liabilities

     (102     (654

Customer deposits and deferred revenue

     4,509        (43
  

 

 

   

 

 

 

Net cash used in operating activities

     (20,286     (20,471
  

 

 

   

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

    

Purchase of property and equipment

     (1,137     (913

Change in restricted cash balance

     500        350   
  

 

 

   

 

 

 

Net cash used in investing activities

     (637     (563
  

 

 

   

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

    

Proceeds from issuance of convertible preferred stock, net

     15,729        (37 )

Proceeds from the exercise of stock options

     10        11  

Proceeds from draw down of long-term debt, net

     27,381        —     

Payments on long-term debt, net

     (15,000     —     

Payments of costs related to the initial public offering

     (628     —     
  

 

 

   

 

 

 

Net cash provided by (used in) financing activities

     27,492        (26
  

 

 

   

 

 

 

NET INCREASE (DECREASE) IN CASH

     6,569        (21,060

CASH—BEGINNING OF PERIOD

     11,129        26,529   
  

 

 

   

 

 

 

CASH—END OF PERIOD

   $ 17,698      $ 5,469   
  

 

 

   

 

 

 

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

    

Cash paid for interest

   $ 963      $ 715   
  

 

 

   

 

 

 

Cash paid for taxes

   $ —       $ —    
  

 

 

   

 

 

 

SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:

    

Purchase of fixed assets in accounts payable

   $ —        $ 254   
  

 

 

   

 

 

 

Deferred offering cost in accrued liabilities

     532      $ —     
  

 

 

   

 

 

 

The accompanying notes are an integral part of these financial statements.

 

5


Index to Financial Statements

VIEWRAY TECHNOLOGIES, INC.

Notes to Financial Statements

(Unaudited)

 

1. Background and Organization

On July 21, 2015, the Company has filed a change of name in its state of incorporation from ViewRay, Inc. to ViewRay Technologies, Inc.

ViewRay Technologies, Inc., or the Company, designs, manufactures and markets MRIdian, the first and only MRI-guided radiation therapy system to image and treat cancer patients simultaneously.

Since inception, the Company has devoted substantially all of its efforts towards research and development, initial selling and marketing activities, raising capital and preparing for the manufacturing and shipment of MRIdian systems. In May 2012, the Company was granted clearance from the U.S. Food and Drug Administration, or FDA, to sell MRIdian. In November 2013, the Company received its first clinical acceptance of a MRIdian at a customer site, and the first patient was treated with that system in January 2014. The Company received permission to affix the CE mark in November 2014.

 

2. Summary of Significant Accounting Policies

The accompanying financial statements reflect the application of certain significant accounting policies, as described below and elsewhere in the accompanying notes to the financial statements.

Basis of Presentation

The financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or GAAP, and pursuant to the rules and regulation of the Securities and Exchanges Commission, or SEC. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s unaudited financial statements have been included. The results of operations for the six months ended June 30, 2015 are not necessarily indicative of the results that may be expected for the year ending December 31, 2015 or any future period. These unaudited financial statements and notes thereto should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2014.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and accompanying notes. Such estimates include, but are not limited to, allocation of revenue to its multiple deliverable elements, inventory write-downs to reflect net realizable value, assumptions used in the valuation of stock-based awards, accrued losses from purchase commitments, and valuation allowances against deferred tax assets. Actual results could differ from those estimates.

Inventory

Inventory consists of purchased components for assembling MRIdian systems and other direct and indirect costs associated with MRIdian system installation. Inventory is stated at the lower of cost or market value. All inventories expected to be placed in service during the Company’s normal operating cycle for the delivery and assembly of MRIdian systems, including items expected to be on hand for more than one year, are classified as current assets.

Effective January 1, 2015, the Company made a voluntary change to its accounting policy for inventory cost basis. Under the previous accounting policy, the Company recorded inventory items on a first-in, first-out basis through specific identification. Purchased components were assigned to each MRIdian system at original cost. Under the new accounting policy, the Company records inventory at weighted average cost basis.

The Company believes that this change is preferable because it will be more efficient for the Company to keep track of its inventory cost. The first-in, first-out cost basis through specific identification accounting policy was

 

6


Index to Financial Statements

manageable at the time since the Company had limited MRIdian system installations (one MRIdian system installation during the year ended December 31, 2013, and another two MRIdian system installation during the year ended December 31, 2014). However, due to the Company’s growing business and sales, the number of planned MRIdian system installation has been increasing. Purchased components are no longer assigned to specific MRIdian system installation. Along with the Company’s increased components purchasing activities, the new accounting policy will significantly reduce the Company’s burden and cost of inventory management.

In accordance with applicable accounting literature, a change in inventory cost basis is treated as a change in accounting principle and requires retrospective application. The accounting policy change has no cumulative effect on the Company’s annual statements of operations prior to January 1, 2015, and immaterial effect on the Company’s interim statements of operations for the year ended December 31, 2014. Therefore, no retrospective adjustment of the Company’s annual financial statements are required, and the Company’s statements of operations for the six months ended June 30, 2014 is not revised for the immaterial impact from the accounting policy change.

 

3. Going Concern

The Company’s unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company currently has limited working capital, and has not completed its efforts to establish a stabilized source of revenues sufficient to cover operating costs over an extended period of time.

Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operating expenses. The Company intends to position itself so that it may be able to raise additional funds through the capital markets. In light of management’s efforts, there are no assurances that the Company will be successful in this or any of its endeavors or become financially viable and continue as a going concern.

 

4. Balance Sheet Components

Property and Equipment

Property and equipment consisted of the following (in thousands):

 

     June 30,
2015
     December 31,
2014
 
     (Unaudited)         

Prototype

   $ 6,451       $ 6,342   

Machinery and equipment

     4,996         4,214   

Leasehold improvements

     1,274         1,270   

Furniture and fixtures

     322         263   

Software

     768         647   
  

 

 

    

 

 

 

Property and equipment, gross

     13,811         12,736   

Less: accumulated depreciation and amortization

     (10,313      (9,805
  

 

 

    

 

 

 

Property and equipment, net

   $ 3,498       $ 2,931   
  

 

 

    

 

 

 

Depreciation and amortization expense related to property and equipment was $508 thousand and $405 thousand during the six months ended June 30, 2015 and 2014.

 

7


Index to Financial Statements

Intangible Assets

Intangible assets consisted of the following (in thousands):

 

     June 30,
2015
     December 31,
2014
 
     (Unaudited)         

Intangible assets—license cost

   $ 500       $ 500   

Accumulated amortization

     (319      (236
  

 

 

    

 

 

 

Intangible assets, net

   $ 181       $ 264   
  

 

 

    

 

 

 

Intangible amortization expense was $83 thousand in both periods during the six months ended June 30, 2015 and 2014, which were recorded in general and administrative expenses in the statements of operations.

At June 30, 2015, the estimated future amortization expense of purchased intangible assets was as follows (in thousands):

 

Year Ending December 31,

   Estimated Future
Amortization
Expense
 

The remainder of 2015

   $ 83   

2016

     98   
  

 

 

 

Total amortization expense

   $ 181   
  

 

 

 

Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

 

     June 30,
2015
     December 31,
2014
 
     (Unaudited)         

Accrued payroll and related benefits

   $ 1,337       $ 1,652   

Accrued accounts payable

     465         946   

Sales tax and medical device excise tax payable

     37         499   

Accrued legal and accounting

     744         901   

Accrued interest

     49         142   

Accrued debt facility fee

     1,509         —    

Other

     447         296   
  

 

 

    

 

 

 

Total accrued liabilities

   $ 4,588       $ 4,436   
  

 

 

    

 

 

 

Deferred Revenue

Deferred revenue consisted of the following (in thousands):

 

     June 30,
2015
     December 31,
2014
 
     (Unaudited)         

Deferred revenue:

     

Product

   $ 9,750       $ 6,919   

Services

     80         442   
  

 

 

    

 

 

 

Total deferred revenue

     9,830         7,361   

Less: current portion of deferred revenue

     (9,830      (7,361
  

 

 

    

 

 

 

Noncurrent portion of deferred revenue

   $ —        $ —    
  

 

 

    

 

 

 

 

8


Index to Financial Statements
5. Fair Value of Financial Instruments

The Company’s financial instruments that are carried at fair value consist of Level 1 assets and Level 3 liabilities. Level 1 assets include highly liquid bank deposits and money market funds, which were not material at June 30, 2015 and December 31, 2014. Level 3 liabilities consist of the convertible preferred stock warrant liability. The convertible preferred stock warrant liability was valued using the Black-Scholes option-pricing model. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value of the warrant (see Note 9).

The convertible preferred stock warrant was issued in December 2013 and, was still outstanding at June 30, 2015 and December 31, 2014. The following table sets forth the fair value of the Company’s financial liabilities by level within the fair value hierarchy (in thousands):

 

     At June 30, 2015  
     Level 1      Level 2      Level 3      Total  
     (Unaudited)  

Convertible preferred stock warrant liability

   $ —         $ —         $ 87       $ 87   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     At December 31, 2014  
     Level 1      Level 2      Level 3      Total  
     (Unaudited)  

Convertible preferred stock warrant liability

   $ —        $ —        $ 138       $ 138   
  

 

 

    

 

 

    

 

 

    

 

 

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities (in thousands):

 

     Six Months
Ended June 30,
2015
 
     (Unaudited)  

Fair value, beginning of period

   $ 138   

Change in fair value of Level 3 financial liabilities

     (51
  

 

 

 

Fair value, end of period

   $ 87   
  

 

 

 

The gains and losses from re-measurement of Level 3 financial liabilities are recorded as part of other income (expense), net in the statements of operations.

 

6. Term Loan

2015 Term Loan

On June 26, 2015, the Company entered into a Term Loan Agreement, or the Term Loan, with Capital Royalty Partners II L.P and Parallel Investment Opportunities Partners II L.P or together, CRG, for up to $50.0 million of which $30.0 million was made available to us upon closing with the remaining $20.0 million to be available on or before June 30, 2016 at our option upon achieving certain milestones. We drew down the first $30.0 million on the closing date. The Term Loan has a maturity date of June 26, 2020 and bears cash interest at a rate of 12.5% per annum to be paid quarterly during the first 3 years. After the first 3 years of interest only payment, we have the option to pay cash interest at a rate of 8% and deferred payment in-kind interest at 4.5% per annum. Principal payment and any deferred payment in-kind interest will be paid quarterly in equal installments following the third year through maturity date.

The Term Loan is subject to a prepayment penalty of 3% on the outstanding balance during the first 12 months following the funding of the Term Loan, 2% on the outstanding balance after year 1 but on or before year 2, 1% on the outstanding balance after year 2 but on or before year 3, and 0% on the outstanding loan if prepaid after year 3 thereafter until maturity. The Term Loan is also subject to a facility fee of 5% based on the sum of the Term Loan

 

9


Index to Financial Statements

drawn and any outstanding payment in-kind payable on maturity date or the date such Term Loan becomes due for whatever reason. All direct financing costs were accounted for as a discount on the Term Loan and will be amortized to interest expense during the life of the Term Loan using the effective interest method. The Term Loan is subject to financial covenants and is collateralized by essentially all our assets and limits the Company’s ability with respect to additional indebtedness, investments or dividends, among other things, subject to customary exceptions.

On June 26, 2015, the Company paid off in full the $13.0 million outstanding term debt with Hercules and the related interest and other penalty fee using part of the proceeds received from the CRG Term Loan.

 

7. Commitments and Contingencies

Operating Leases

The Company leases office space in Oakwood Village, Ohio and Mountain View, California under non-cancellable operating leases. At December 31, 2014, the future minimum payments for the operating leases are as follows (in thousands):

 

Year Ending December 31,

   Future Minimum
Payments
 

2015

   $ 1,086   

2016

     1,113   

2017

     1,106   

2018

     963   

2019 and thereafter

     823   
  

 

 

 

Total future minimum payments

   $ 5,091   
  

 

 

 

Contingencies

The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount.

In the normal course of business, the Company may become involved in legal proceedings. The Company will accrue a liability for such matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. When only a range of possible loss can be established, the most probable amount in the range is accrued. If no amount within this range is a better estimate than any other amount within the range, the minimum amount in the range is accrued. The accrual for a litigation loss contingency might include, for example, estimates of potential damages, outside legal fees and other directly related costs expected to be incurred. At June 30, 2015 and December 31, 2014, the Company was not involved in any material legal proceedings.

Purchase Commitments

At June 30, 2015, the Company had no outstanding firm purchase commitments.

 

8. Convertible Preferred Stock

In January 2015, the Company issued an aggregate of 162,407 shares of Series C convertible preferred stock to a new investor at a price of $5.85 per share for a total gross consideration of $950 thousand.

In February 2015, the Company issued 2,564,652 shares of Series C convertible preferred stock to another investor at a price of $5.85 per share for total gross consideration of $15.0 million.

The rights, privileges and preferences of the issued Series C convertible preferred stock in January and February 2015 are the same as the Series C convertible preferred stock outstanding as of December 31, 2014.

 

10


Index to Financial Statements

Convertible preferred stock as of June 30, 2015 and December 31, 2014 consisted of the following (in thousands, except share data):

 

     June 30, 2015  
     Shares
Authorized
     Shares Issued
and
Outstanding
     Aggregate
Liquidation
Preference
     Net Carrying
Value
 
            (Unaudited)         

Series A

     398,500         162,109       $ 3,004       $ 3,003   

Series B

     60,500,000         22,308,230         113,405         112,080   

Series C

     19,812,497         7,911,648         46,273         45,756   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     80,710,997         30,381,987       $ 162,682       $ 160,839   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     December 31, 2014  
     Shares
Authorized
     Shares Issued
and
Outstanding
     Aggregate
Liquidation
Preference
     Net Carrying
Value
 
            (Unaudited)         

Series A

     398,500         162,109       $ 3,004       $ 3,003   

Series B

     60,500,000         22,308,230         113,405         112,080   

Series C

     13,562,497         5,184,589         30,323         30,027   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     74,460,997         27,654,928       $ 146,732       $ 145,110   
  

 

 

    

 

 

    

 

 

    

 

 

 

 

9. Convertible Preferred Stock Warrant

The Company has an outstanding convertible preferred stock warrant related to a 2013 debt financing whereby the Company issued a warrant to purchase 128,231 shares of Series C convertible preferred stock. The convertible preferred stock warrant was recorded as a liability and is adjusted to fair value at each balance sheet date, with the change in fair value being recorded as a component of other income (expense), net in the statements of operations. Upon issuance, the fair value of the warrant was estimated to be $158 thousand. The Company recorded a gain of $51 thousand related to the change in fair value of preferred stock warrant liability as part of other income (expense), net in the accompanying statements of operations for the six months ended June 30, 2015. The change in fair value of the preferred stock warrant liability was immaterial during the six months ended June 30, 2014.

The key terms of the outstanding convertible preferred stock warrant and the convertible preferred stock warrant liability at June 30, 2015 and December 31, 2014 were as follows (in thousands):

 

     Issuance Date     

Expiration Date

   Exercise
Price Per
Share
     Shares      Fair Value of Warrant  
               June 30,
2015
     December 31,
2014
 
                               (Unaudited)         

Series C Warrant

     December 2013       The later of December 2023 or five years after an IPO    $ 2.40         128,231       $ 87       $ 138   

The Company used the Black-Scholes option-pricing model to estimate the fair value of the convertible preferred stock warrant with the following assumptions:

 

     June 30,
2015
    December 31,
2014
 
     (Unaudited)        

Series C Warrant:

    

Expected term (in years)

     5.04        5.3   

Expected volatility

     30.0     30.0

Risk-free interest rate

     1.6     1.7

Expected dividend yield

     0     0

 

11


Index to Financial Statements
10. Stock-Based Compensation

A summary of the Company’s stock option activity and related information is as follows:

 

           Options Outstanding  
     Shares
Available
for Grant
    Number
of Stock
Options
Outstanding
    Weighted-
Average
Exercise
Price
     Weighted-
Average
Remaining
Contractual
Life
(Years)
     Aggregate
Intrinsic
Value
 
                               (In thousands)  

Balance at December 31, 2014

     295,101        4,248,519      $ 0.76         7.7       $ 8,343   

Granted (unaudited)

     (104,808     104,808        2.72         

Exercised (unaudited)

     —         (13,814     0.74         

Cancelled (unaudited)

     83,210        (83,210     1.12         
  

 

 

   

 

 

         

Balance at June 30, 2015 (unaudited)

     273,503        4,256,303      $ 0.80         7.2       $ 17,888   
  

 

 

   

 

 

         

Vested and exercisable at June 30, 2015 (unaudited)

       2,695,883      $ 0.72         6.5       $ 11,540   

Vested and expected to vest at June 30, 2015 (unaudited)

       3,914,636      $ 0.78         7.2       $ 16,516   

The weighted-average grant date fair value of options granted to employees during the six months ended June 30, 2015 and 2014 was $1.37 and $0.36 per share. There were 1,461,759 options granted during the six months ended June 30, 2014. The grant date fair value of options vested during the six months ended June 30, 2015 and 2014 was $61 thousand and $100 thousand.

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options.

At June 30, 2015, total unrecognized compensation cost related to stock-based awards granted to employees, net of estimated forfeitures, was $639 thousand which is expected to be recognized over a weighted-average period of 2.6 years.

Determination of Fair Value

The determination of the fair value of stock options on the date of grant using an option-pricing model is affected by the estimated fair value of the Company’s common stock, as well as assumptions regarding a number of complex and subjective variables. The variables used to calculate the fair value of stock options using the Black-Scholes option-pricing model include actual and projected employee stock option exercise behaviors, expected price volatility of the Company’s common stock, the risk-free interest rate and expected dividends. Each of these inputs is subjective and generally requires significant judgment to determine.

Fair Value of Common Stock

The fair value of the common stock underlying the stock-based awards was determined by the Company’s board of directors, with input from management and third-party valuations.

 

12


Index to Financial Statements

Expected Term

The expected term represents the period that the Company’s option awards are expected to be outstanding. The Company considers several factors in estimating the expected term of options granted, including the expected lives used by a peer group of companies within the Company’s industry that the Company considers to be comparable to its business and the historical option exercise behavior of its employees, which the Company believes is representative of future behavior.

Expected Volatility

As the Company does not have a trading history for its common stock, the expected stock price volatility for the Company’s common stock was estimated by taking the average historic price volatility for industry peers based on daily price observations over a period equivalent to the expected term of the stock option grants. Industry peers consist of several public companies in the Company’s industry which were the same as the comparable companies used in the common stock valuation analysis. The Company intends to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of its own share price becomes available, or unless circumstances change such that the identified companies are no longer similar to the Company, in which case, more suitable companies whose share prices are publicly available would be used in the calculation.

Risk-Free Interest Rate

The risk-free interest rate is based on the zero coupon U.S. Treasury notes, with maturities similar to the expected term of the options.

Expected Dividend Yield

The Company does not anticipate paying any dividends in the foreseeable future and, therefore, uses an expected dividend yield of zero in the Black-Scholes option-valuation model.

In addition to the Black-Scholes assumptions discussed immediately above, the estimated forfeiture rate also has a significant impact on the related stock-based compensation. The forfeiture rate of stock options is estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest.

For the six months ended June 30, 2015, the weighted average fair value of employee stock options was estimated at the date of grant using a Black-Scholes option-pricing model with the following assumptions. There were no option grants during the six months ended June 30, 2014.

 

     June 30,
2015
 
     (Unaudited)  

Expected term (in years)

     5.98   

Expected volatility

     52.3

Risk-free interest rate

     1.6

Expected dividend yield

     0

Stock-Based Compensation Expense

Total stock-based compensation expense recognized in the Company’s statements of operations is classified as follows (in thousands):

 

     Six Months Ended June 30,  
     2015      2014  
     (Unaudited)  

Research and development

   $ 48       $ 56   

Selling and marketing

     10         8   

General and administrative

     90         140   
  

 

 

    

 

 

 

Total stock-based compensation expense

   $ 148       $ 204   
  

 

 

    

 

 

 

 

13


Index to Financial Statements

During the six months ended June 30, 2015 and 2014, there were no stock-based compensation expenses capitalized as a component of inventory or recognized in cost of revenue. Stock-based compensation relating to stock-based awards granted to consultants was insignificant for the six months ended June 30, 2015 and 2014.

 

11. Net Loss per Share

The following table sets forth the computation of the Company’s basic and diluted net loss per share for the periods presented (in thousands, except share and per share data):

 

     Six Months Ended June 30,  
     2015      2014  
     (Unaudited)  

Net loss

   $ (20,629    $ (16,611

Gain due to repurchase of Series A preferred stock

     —           9   
  

 

 

    

 

 

 

Net loss attributable to common stockholders

   $ (20,629    $ (16,602
  

 

 

    

 

 

 

Weighted-average common shares used in computing net loss per share, basic and diluted

     916,017         880,708   
  

 

 

    

 

 

 

Net loss per share, basic and diluted

   $ (22.52    $ (18.85
  

 

 

    

 

 

 

The following weighted-average common stock equivalents were excluded from the calculation of diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect:

 

     Six Months Ended June 30,  
     2015      2014  
     (Unaudited)  

Convertible preferred stock (if converted)

     29,698,312         25,035,381   

Options to purchase common stock

     4,269,189         3,999,228   

Convertible preferred stock warrant (if converted)

     128,231         128,231   

 

12. Subsequent Events

On July 21, 2015, the Company has filed a change of name in its state of incorporation from ViewRay, Inc. to ViewRay Technologies, Inc.

On July 23, 2015, Vesuvius Acquisition Corp., a corporation formed in the State of Delaware on July 16, 2015, or the Acquisition Sub, merged with and into ViewRay Technologies, Inc., a corporation incorporated in 2004 in the state of Florida originally under the name of ViewRay Incorporated, subsequently reincorporated in Delaware in 2007, referred to as ViewRay. Pursuant to this transaction, or the Merger, ViewRay was the surviving corporation and became a wholly-owned subsidiary. All of the outstanding stock of ViewRay was converted into shares of the surviving corporation’s common stock.

In connection with the Merger and pursuant to the Split-Off Agreement, the former shell company transferred its pre-Merger assets and liabilities to the former shell company’s pre-Merger majority stockholder, in exchange for the surrender by her and cancellation of 4,150,171 shares of the surviving corporation.

As a result of the Merger and Split-Off, the former shell company discontinued its pre-Merger business and acquired the business of ViewRay and will continue the existing business operations of ViewRay as a publicly-traded company under the name ViewRay Technologies, Inc.

At July 23, 2015, the Company effected a 2.975-for-1 stock split of the Company’s then outstanding common stock and convertible preferred stock (collectively referred to as “Capital Stock”) and convertible preferred stock warrants, in which (i) each share of outstanding Capital Stock was increased into 2.975 shares of Capital Stock; (ii) the

 

14


Index to Financial Statements

number of outstanding options to purchase each Capital Stock was proportionately increased on a 2.975-for-1 basis; (iii) number of shares reserved for future option grants under the 2008 Plan were proportionately increased on a 2.975-for-1 basis; (iv) the exercise price of each such outstanding option was proportionately decreased on a 2.975-for-1 basis; and (v) each share of outstanding convertible preferred stock warrant was increased into 2.975 shares of convertible preferred stock warrant. All of the share and per share amounts have been adjusted, on a retroactive basis, to reflect this 2.975-for-1 stock split.

The Company has evaluated subsequent events through August 13, 2015, the date on which these consolidated financial statements were issued. No significant subsequent events to this date would have had material impact on the Company’s consolidated financial statements as of and for the six months ended June 30, 2015.

 

15